Cite

HARVARD Citation

    Yamazaki, H. et al. (2022). Could high-dose-rate monotherapy survive beyond stereotactic ablative radiotherapy era for clinically localized prostate cancer?. Radiotherapy and oncology. pp. 97-98. [Online]. 
  
Back to record